Abstract
We studied the effects of alendronate (Aln) and strontium ranelate (SrR) administration on cancellous and cortical bone in glucocorticoid (GC)-treated rats. Thirty-two 3.5-month male Sprague-Dawley rats were randomized into four groups: age-matched normal control (Nrm), methylprednisolone (Met; 5.0 mg/kg/day, sc, for 5 days/week), Met plus Aln orally (1.0 mg/kg/day), and Met plus SrR orally (900 mg/kg/day). The study period was 9 weeks. DXA was used to evaluate the femoral diaphysis and fifth lumbar vertebra (L5). Histomorphometry was performed in the proximal tibial metaphysis and tibial diaphysis. Met significantly decreased body weight and bone mineral density (BMD) compared with Nrm. Aln and SrR significantly increased body weight and BMD compared with Met. SrR resulted in significantly higher BMD than Aln. Met markedly decreased BV/TV, Tb.Th, and Tb.N and increased Tb.Sp compared with Nrm. Aln and SrR showed significantly increased of BV/TV, Tb.Th, and Tb.N and improved bone architecture. Moreover, Met reduced %Ct.Ar, enlarged %Ma.Ar, and decreased bone formation indices in the periosteum as well as increased ES/BS in the endosteum compared with Nrm. Aln significantly decreased endosteal ES/BS compared with Met. SrR significantly increased %Ct.Ar and bone formation indices in the periosteum as well as the endosteum and decreased endosteal ES/BS compared with Met. Furthermore, SrR led to a significantly higher cancellous and endocortical MS/BS and endocortical bone formation compared with Aln. Our findings suggest SrR at a dose of 900 mg/kg has a greater effect than Aln at 1.0 mg/kg, according to BMD and histomorphometric analysis, in preventing GC-induced osteopenia. Therefore, SrR might be applicable as a bone therapeutic agent to treat secondary osteoporosis in the clinic.
Similar content being viewed by others
References
Namkung-Matthai H, Seale JP, Brown K et al (1998) Comparative effects of anti- inflammatory corticosteroids in human bone-derived osteoblast-like cells. Eur Respir J 12:1327–1333
Sambrook P, Hughes D, Nelson AE et al (2003) Osteocyte viability with glucocorticoid therapy: relation to histomorphometry. Ann Rheum Dis 62:1215–1217
Takahashi N, Sasaki T, Tsouderos Y et al (2003) S12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18:1082–1087
Mazziotti G, Angeli A, Bilezikian JP et al (2006) Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 7:144–149
Dalle Carbonare L, Arlot ME, Chavassieux PM et al (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97–103
Dempster DW (1989) Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4:137–141
Chappard D, Legrand E, Basle MF et al (1996) Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 11:676–685
Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000
Masaki H, Miki T (2006) The biochemical markers of bone in steroid (glucocorticoid)-induced osteoporosis (GIOP). Clin Calcium 16:51–60
De Nijs RN (2008) Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med 99:23–43
Mosekilde L, Thomsen JS, Mackey MS et al (2000) Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 27:639–645
Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299
Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 134:604–610
Iwamoto J, Seki A, Takeda T et al (2006) Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia. J Nutr Sci Vitaminol (Tokyo) 52:212–217
Lam S, Zouzias K (2007) Strontium ranelate for the management of osteoporosis. Consult Pharm 23:531–537
Cebesoy O, Tutar E, Kose KC et al (2007) Effect of strontium ranelate on fracture healing in rat tibia. Joint Bone Spine 74:590–593
Bain SD, Jerome C, Shen V et al (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20:1417–1428
Hott M, Deloffre P, Tsouderos Y et al (2003) S12911-2 reduced bone loss induced by short-term immobilization in rats. Bone 33:115–123
Hulley PA, Conradie MM, Langeveldt CR et al (2002) Glucocorticoid induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate. Bone 31:220–229
Ammann P, Badoud I, Barraud S et al (2007) Treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 22:1419–1425
Parfitt AM, Drezner MK, Glorieux FH et al (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610
Ogoshi T, Hagino H, Fukata S et al (2008) Influence of glucocorticoid on bone in 3-, 6-, and 12-month-old rats as determined by bone mass and histomorphometry. Mod Rheumatol 18:55–61
King CS, Weir EC, Gundberg CW et al (1996) Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif Tissue Int 59:184–191
Iwamoto J, Seki A, Takeda T et al (2008) Effects of combined administration of alfacalcidol and risedronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats. Chin J Physiol 51:121–128
Iwamoto J, Matsumoto H, Tadeda T et al (2009) Comparison of the effect of vitamin K2 and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study. Yonsei Med J 50:189–194
Shane E, Addesso V, Namerow PB et al (2004) Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767–776
Roschger P, Rinnerthaler S, Yates JA et al (2001) Alendronate increases degree and uniformity of mineralisation in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185–191
Fratzl P, Roschger P, Fratzl-Zelman N et al (2007) Evidence that treatment with risedronate in women with post menopausal osteoporosis affects bone mineralisation and bone volume. Calcif Tissue Int 81:73–80
Iwamoto J, Matsumoto H, Takeda T et al (2008) Effects of vitamin K2 and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats. Calcif Tissue Int 83:121–128
Bonnelye E, Chabadel A, Saltel F et al (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42:129–138
Arlot ME, Jiang Y, Genant HK et al (2008) Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23:215–222
Marie PJ (2006) Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone 38(Suppl 1):10–14
Marie PJ, Hott M, Modrowski D et al (1993) An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8:607–615
Marie PJ, Hott M (1986) Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Metabolism 35:547–551
Boivin G, Deloffre P, Perrat B et al (1996) Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 11:1302–1311
Grynpas M, Marie PJ (1990) Effects of low doses of strontium on bone quality and quantity in rats. Bone 11:313–319
Acknowledgments
This work was supported by the National Natural Science Foundation of China (30971172). The authors are grateful to Ke Fang (doctoral student, Division of Counseling Psychology, Department of Educational and Counseling Psychology, School of Education, State University of New York at Albany) for her excellent English editorial assistance.
Author information
Authors and Affiliations
Corresponding authors
Additional information
The authors have stated that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Sun, P., Cai, D.H., Li, Q.N. et al. Effects of Alendronate and Strontium Ranelate on Cancellous and Cortical Bone Mass in Glucocorticoid-Treated Adult Rats. Calcif Tissue Int 86, 495–501 (2010). https://doi.org/10.1007/s00223-010-9363-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-010-9363-2